2026-08-31 02:03
Economic Observation Network Quick and Precision Medicine (QGEN) disclosed financial data for the first half of 2026, with a slight increase in revenue year-on-year and a decline in net profit year-on-year. The cumulative stock price has fallen by about 11.7% since the beginning of the year.
Performance and business situation:
In the first half of 2026, the revenue was 1.027 billion US dollars (+1% year-on-year), and the net profit was 171 million US dollars (-8.3% year-on-year)
The above content is based on publicly available information and does not constitute investment advice.
From resistance to embrace, takeaway has become a rare highlight in the catering industry in the first half of the year
You can get a license anywhere, but young people don't get married because it's inconvenient
Low altitude track differentiation: rapid development of industrial drones, temporary slowdown in commercialization of eVTOL
